Understanding the impact of neoadjuvant chemotherapy on the immune microenvironment in Pancreatic Ductal Adenocarcinoma (PDAC)
|SPEAKER:||Greg Lesinski, PhD, MPH, Associate Professor Department of Hematology and Medical Oncology, Emory University School of Medicine|
Oct 30, 2018
Pancreatic ductal adenocarcinoma (PDAC) has been refractory to immunotherapy and is characterized by a complex, stroma-rich tumor microenvironment. Most patients undergo treatment with aggressive chemotherapeutic regimens, which may alter the cellular composition and immunologic landscape within these tumors. To date, few studies have characterized the impact of chemotherapy on individual cellular compartments within PDAC tumors. We hypothesized that neoadjuvant chemotherapy may differentially modulate immune factors in the tumor, stroma and immune-cell rich regions of human PDAC tumors. We compared the spatial expression of 31 immuno-oncology targets across PDAC FFPE specimens from FOLFIRINOX and non-treated patients (n=5 each). Using the Digital Spatial Profiling technology from Nanostring®, we were able to identify FOLFIRINOX treatment results in significant spatially-distinct changes in protein expression.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.